BM201 / InnoBM Pharma - LARVOL DELTA

Clinical efficacy, safety, and PK/PD from the first in human study of BM201, a TLR7/8 agonist (ESMO Asia 2024) - P1 | "Conclusions BM201 has a favorable safety profile and has shown encouraging anti-tumor activity in the dose escalation phase. Follow-up is still ongoing."

Clinical • P1 data • PK/PD data • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor